Intervention

XNW5004

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting1

Common conditions10

Lead sponsors shown1

Clinical trials

2 shown

Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerNCT06702995 · 2023-04-19

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)NCT06022757 · 2023-09-20

Common conditions

Carcinoma1 Cervical Cancer1 mCRPC (Metastatic Castration-resistant Prostate Cancer)1 Metastatic Castrate-Resistant Prostate Cancer1 Non-small Cell Lung Cancer1 Other Solid Tumors1 Prostate Cancer1 Small-cell Lung Cancer1 Squamous Cell Carcinoma of Head and Neck1 Urothelial Carcinoma1

Leading sponsors

Evopoint Biosciences Inc.2

Trial status mix

RECRUITING1

TERMINATED1

Phase mix

PHASE12

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.